{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:48:21Z","timestamp":1784306901859,"version":"3.55.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1053\/j.seminhematol.2024.08.005","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T23:57:31Z","timestamp":1724543851000},"page":"290-296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["CARs Moving Forward: The Development of CAR T-Cell Therapy in the Earlier Treatment Course of Hematologic Malignancies"],"prefix":"10.1053","volume":"61","author":[{"given":"Omar","family":"Castaneda Puglianini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2045-6238","authenticated-orcid":false,"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1053\/j.seminhematol.2024.08.005_bib0001","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.08.005_bib0002","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.08.005_bib0003","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"16","key":"10.1053\/j.seminhematol.2024.08.005_bib0004","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.08.005_bib0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ajh.24615","article-title":"Diffuse large B-cell lymphoma with primary treatment failure: ultra-high risk features and benchmarking for experimental therapies","volume":"92","author":"Costa","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.08.005_bib0006","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.08.005_bib0007","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10254","key":"10.1053\/j.seminhematol.2024.08.005_bib0008","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.08.005_bib0009","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.08.005_bib0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.08.005_bib0011","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.08.005_bib0012","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1182\/blood-2023-174914","article-title":"Axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory indolent non-hodgkin lymphoma: 4-year follow-up from the phase 2 ZUMA-5 trial","volume":"142","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.08.005_bib0013","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.08.005_bib0014","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.08.005_bib0015","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood-2023-180936","article-title":"Clinical outcomes of patients with relapsed\/refractory follicular lymphoma treated with tisagenlecleucel: phase 2 elara 3-year follow-up","volume":"142","author":"Schuster","year":"2023","journal-title":"Blood"},{"issue":"S2","key":"10.1053\/j.seminhematol.2024.08.005_bib0016","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/hon.3196_LBA4","article-title":"TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS (PTS) WITH RELAPSED\/REFRACTORY (R\/R) FOLLICULAR LYMPHOMA (FL)","volume":"41","author":"Morschhauser","year":"2023","journal-title":"Hematological Oncology"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.08.005_bib0017","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.08.005_bib0018","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.08.005_bib0019","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.08.005_bib0020","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1182\/blood-2023-174273","article-title":"Outcomes of patients with relapsed\/refractory mantle cell lymphoma (R\/R MCL) treated with brexucabtagene autoleucel (Brexu-cel) in ZUMA-2 and ZUMA-18, an expanded access study","volume":"142","author":"Goy","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.08.005_bib0021","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7897","key":"10.1053\/j.seminhematol.2024.08.005_bib0022","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"issue":"10402","key":"10.1053\/j.seminhematol.2024.08.005_bib0023","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"27","key":"10.1053\/j.seminhematol.2024.08.005_bib0024","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1053\/j.seminhematol.2024.08.005_bib0025","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.08.005_bib0026","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/bmt.2016.213","article-title":"Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study","volume":"52","author":"Van Den Neste","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.08.005_bib0027","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large b-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.08.005_bib0028","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive b-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1053\/j.seminhematol.2024.08.005_bib0029","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.08.005_bib0030","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.08.005_bib0031","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.08.005_bib0032","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood.V124.21.3069.3069","article-title":"Outcome in unselected patients with relapsed\/refractory diffuse large B-cell lymphoma (DLBCL) following R-CHOP when stem cell transplantation is not feasible","volume":"124","author":"Kansara","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.08.005_bib0033","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejca.2022.08.019","article-title":"Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population","volume":"175","author":"Vic","year":"2022","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.08.005_bib0034","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.08.005_bib0035","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/blood-2023-180952","article-title":"Lisocabtagene maraleucel as second-line therapy for R\/R large B-cell lymphoma in patients not intended for hematopoietic stem cell transplant: final analysis of the phase 2 PILOT study","volume":"142","author":"Sehgal","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.08.005_bib0036","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1038\/s41591-023-02572-5","article-title":"Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial","volume":"29","author":"Houot","year":"2023","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.08.005_bib0037","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1182\/blood-2023-179474","article-title":"TRANSCEND FL: phase 2 study primary analysis of lisocabtagene maraleucel as second-line therapy in patients with high-risk relapsed or refractory follicular lymphoma","volume":"142","author":"Morschhauser","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.08.005_bib0038","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7579","article-title":"ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R\/R) follicular lymphoma (FL)","volume":"41","author":"Flinn","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.08.005_bib0039","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1182\/bloodadvances.2023011532","article-title":"Outcomes of subsequent anti-lymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7","volume":"8","author":"Ghobadi","year":"2024","journal-title":"Blood Adv"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.08.005_bib0040","doi-asserted-by":"crossref","first-page":"djw257","DOI":"10.1093\/jnci\/djw257","article-title":"Beyond RCHOP: a blueprint for diffuse large B cell lymphoma research","volume":"108","author":"Nowakowski","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.08.005_bib0041","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJMc2306105","article-title":"Cell-of-origin subtypes and therapeutic benefit from polatuzumab vedotin","volume":"389","author":"Palmer","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.08.005_bib0042","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"},{"issue":"27","key":"10.1053\/j.seminhematol.2024.08.005_bib0043","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.08.005_bib0044","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7578","article-title":"ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma","volume":"41","author":"Westin","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.08.005_bib0045","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","article-title":"A novel autologous CAR-T Therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development","volume":"13","author":"Dickinson","year":"2023","journal-title":"Cancer Discov"},{"issue":"S2","key":"10.1053\/j.seminhematol.2024.08.005_bib0046","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/hon.3163_112","article-title":"MRD-NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYSIS OF 6 CLINICAL TRIALS","volume":"41","author":"Roschewski","year":"2023","journal-title":"Hematological Oncology"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.08.005_bib0047","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.08.005_bib0048","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"10297","key":"10.1053\/j.seminhematol.2024.08.005_bib0049","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.08.005_bib0050","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.08.005_bib0051","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an Anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.08.005_bib0052","doi-asserted-by":"crossref","first-page":"e691","DOI":"10.1097\/HS9.0000000000000691","article-title":"Changing the natural history of multiple myeloma","volume":"6","author":"Puertas","year":"2022","journal-title":"Hemasphere"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.08.005_bib0053","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1182\/blood-2023-178798","article-title":"Patient-reported outcomes in the phase 3 CARTITUDE-4 study of ciltacabtagene autoleucel vs standard of care in patients with lenalidomide-refractory multiple myeloma after 1-3 lines of therapy","volume":"142","author":"Mina","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.08.005_bib0054","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2352-3026(24)00005-X","volume":"11","author":"Delforge","year":"2024","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.08.005_bib0055","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2023-178882","article-title":"The phase 2 CARTITUDE-2 trial: updated efficacy and safety of ciltacabtagene autoleucel in patients with multiple myeloma and 1-3 prior lines of therapy (Cohort A) and with early relapse after first line treatment (Cohort B)","volume":"142","author":"Hillengass","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.08.005_bib0056","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2022-162469","article-title":"KarMMa-2 cohort 2a: efficacy and safety of idecabtagene vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation","volume":"140","author":"Usmani","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.08.005_bib0057","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1182\/blood-2022-162615","article-title":"KarMMa-2 cohort 2c: efficacy and safety of idecabtagene vicleucel in patients with clinical high-risk multiple myeloma due to inadequate response to frontline autologous stem cell transplantation","volume":"140","author":"Dhodapkar","year":"2022","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1053\/j.seminhematol.2024.08.005_bib0058","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8053","article-title":"KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma","volume":"39","author":"Usmani","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.08.005_bib0059","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2021-146210","volume":"138","author":"Dytfeld","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.08.005_bib0060","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1182\/blood-2022-157021","article-title":"DVRd followed by ciltacabtagene autoleucel versus DVRd followed By ASCT in patients with newly diagnosed multiple myeloma who are transplant eligible: a randomized phase 3 study (EMagine\/CARTITUDE-6)","volume":"140","author":"Boccadoro","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.08.005_bib0061","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2023-174841","article-title":"Updated results of a phase i open-label single-arm study of dual targeting BCMA and CD19 fastcar-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma","volume":"142","author":"Du","year":"2023","journal-title":"Blood"},{"issue":"16","key":"10.1053\/j.seminhematol.2024.08.005_bib0062","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.08.005_bib0063","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.08.005_bib0064","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.08.005_bib0065","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.08.005_bib0066","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.08.005_bib0067","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10299","key":"10.1053\/j.seminhematol.2024.08.005_bib0068","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.08.005_bib0069","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1200\/JCO.2022.40.16_suppl.7010","article-title":"Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (Pts) with relapsed\/refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL) in ZUMA-3","volume":"40","author":"Shah","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.08.005_bib0070","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.08.005_bib0071","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-023-00813-x","article-title":"CD19\/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study","volume":"13","author":"Niu","year":"2023","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.08.005_bib0072","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jtct.2023.01.012","article-title":"Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: a multi-institution experience","volume":"29","author":"Kourelis","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1053\/j.seminhematol.2024.08.005_bib0073","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.19.00086","article-title":"Impact of increasing wait times on overall mortality of chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a discrete event simulation model","volume":"3","author":"Tully","year":"2019","journal-title":"JCO Clinical Cancer Informatics"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.08.005_bib0074","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.1182\/bloodadvances.2022008106","article-title":"Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL","volume":"6","author":"Abramson","year":"2022","journal-title":"Blood Adv"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.08.005_bib0075","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood.2022015478","article-title":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma","volume":"140","author":"Elsawy","year":"2022","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2024.08.005_bib0076","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1200\/JCO.2022.40.16_suppl.6567","article-title":"Lisocabtagene maraleucel (liso-cel) as second-line (2L) treatment (tx) for R\/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): patient-reported outcomes (PRO) from the phase 2 PILOT study","volume":"40","author":"Gordon","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.08.005_bib0077","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamanetworkopen.2022.45956","article-title":"Cost-effectiveness of axicabtagene ciloleucel and tisagenlecleucel as second-line or later therapy in relapsed or refractory diffuse large B-cell lymphoma","volume":"5","author":"Choe","year":"2022","journal-title":"JAMA Network Open"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.08.005_bib0078","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.7326\/M22-2276","article-title":"Second-line chimeric antigen receptor T-cell therapy in diffuse large b-cell lymphoma : a cost-effectiveness analysis","volume":"176","author":"Kelkar","year":"2023","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.08.005_bib0079","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1182\/bloodadvances.2023011793","article-title":"Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma","volume":"8","author":"Choe","year":"2024","journal-title":"Blood Advances"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.08.005_bib0080","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/blood-2023-179424","article-title":"Primary analysis of varnimcabtagene autoleucel (IMN-003A) in phase 2 study (IMAGINE), a first-in-India industry CD19-directed CAR-T cell therapy for patients with relapsed refractory B cell malignancies","volume":"142","author":"Damodar","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.08.005_bib0081","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/1078-0432.CCR-23-3759","article-title":"Biomarkers of efficacy and safety of the academic BCMA-CART ARI0002h for the treatment of refractory multiple myeloma","volume":"30","author":"Oliver-Caldes","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.08.005_bib0082","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jtct.2022.02.017","article-title":"Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma","volume":"28","author":"Kedmi","year":"2022","journal-title":"Transplant Cell Ther"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T17:11:40Z","timestamp":1729012300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324000891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":82,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0037196324000891"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.08.005","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CARs Moving Forward: The Development of CAR T-Cell Therapy in the Earlier Treatment Course of Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}